KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbbVie (ABBV) Research & Development (2016 - 2026)

AbbVie has reported Research & Development over the past 14 years, most recently at $2.6 billion for Q4 2025.

  • Quarterly Research & Development fell 61.93% to $2.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 billion through Dec 2025, down 28.89% year-over-year, with the annual reading at $9.1 billion for FY2025, 28.89% down from the prior year.
  • Research & Development was $2.6 billion for Q4 2025 at AbbVie, up from $2.3 billion in the prior quarter.
  • Over five years, Research & Development peaked at $6.8 billion in Q4 2024 and troughed at $1.5 billion in Q1 2022.
  • The 5-year median for Research & Development is $1.9 billion (2021), against an average of $2.1 billion.
  • Year-over-year, Research & Development soared 251.53% in 2024 and then plummeted 61.93% in 2025.
  • A 5-year view of Research & Development shows it stood at $1.8 billion in 2021, then fell by 2.03% to $1.8 billion in 2022, then increased by 7.65% to $1.9 billion in 2023, then soared by 251.53% to $6.8 billion in 2024, then plummeted by 61.93% to $2.6 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Research & Development are $2.6 billion (Q4 2025), $2.3 billion (Q3 2025), and $2.1 billion (Q2 2025).